Harnessing unconjugated bilirubin as an endogenous antimalarial weapon exploits its dual sabotage of parasite mitochondrial pyrimidine synthesis and hemozoin crystallization. Pharmacologically blocking UGT1A1 conjugation elevates bilirubin levels, creating metabolic vulnerabilities that synergize with existing drugs by weaponizing the jaundice defense axis against Plasmodium falciparum.